{"results": {"-23606197136376385": {"type": "Activation", "subj": {"name": "USP47", "db_refs": {"UP": "Q96K76", "TEXT": "USP47", "HGNC": "20076", "EGID": "55031"}}, "obj": {"name": "MDM2", "db_refs": {"UP": "Q00987", "HGNC": "6973", "EGID": "4193", "TEXT": "MDM2"}}, "obj_activity": "activity", "belief": 0.37152225, "evidence": [{"source_api": "reach", "text": "In addition to P5091, a dual inhibitor of USP7 and USP47, compound 1 ( Table 2 ) (IC 50 = 4.2 \u03bcM for USP7 and IC 50 = 4.3 \u03bcM for USP47) [86] accelerated MDM2 degradation in human cancer cell lines and[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]", "annotations": {"found_by": "Positive_activation_syntax_1_verb", "agents": {"raw_text": ["USP47", "MDM2"]}, "prior_uuids": ["a974bfb6-c13d-40ae-a471-142940f5854f"], "content_source": "elsevier"}, "epistemics": {"direct": false, "raw_sections": []}, "text_refs": {"PMID": "33157193", "TRID": 32355039, "PMID_NUM": 33157193, "DOI": "10.1016/J.DRUDIS.2020.10.028", "DOI_NS": 1016, "DOI_ID": "J.DRUDIS.2020.10.028", "PII": "S1359-6446(20)30464-5", "TCID": 88844991, "SOURCE": "elsevier", "RID": 10300088844991, "READER": "REACH"}, "source_hash": -6226856005742733743, "pmid": "33157193"}], "id": "a974bfb6-c13d-40ae-a471-142940f5854f", "matches_hash": "-23606197136376385"}}, "limit": 500, "offset": null, "next_offset": null, "query_json": {"class": "SourceIntersection", "constraint": {"source_queries": [{"class": "HasHash", "constraint": {"stmt_hashes": ["-23606197136376385"]}, "inverted": false}, {"class": "HasOnlySource", "constraint": {"only_source": "medscan"}, "inverted": true}]}, "inverted": false}, "evidence_counts": {"-23606197136376385": 1}, "belief_scores": {"-23606197136376385": 0.37152225}, "source_counts": {"-23606197136376385": {"hprd": 0, "tkg": 0, "omnipath": 0, "biogrid": 0, "minerva": 0, "tees": 0, "pc": 0, "isi": 0, "wormbase": 0, "signor": 0, "conib": 0, "geneways": 0, "reach": 1, "creeds": 0, "pe": 0, "psp": 0, "cbn": 0, "gnbr": 0, "dgi": 0, "vhn": 0, "trrust": 0, "acsn": 0, "drugbank": 0, "eidos": 0, "rlimsp": 0, "semrep": 0, "tas": 0, "bel_lc": 0, "trips": 0, "ubibrowser": 0, "ctd": 0, "crog": 0, "sparser": 0}}, "total_evidence": 1, "result_type": "statements", "offset_comp": 1, "returned_evidence": 1, "statement_limit": 500, "statements_returned": 1, "end_of_statements": true, "statements_removed": 0, "evidence_returned": 1, "statements": {"-23606197136376385": {"type": "Activation", "subj": {"name": "USP47", "db_refs": {"UP": "Q96K76", "TEXT": "USP47", "HGNC": "20076", "EGID": "55031"}}, "obj": {"name": "MDM2", "db_refs": {"UP": "Q00987", "HGNC": "6973", "EGID": "4193", "TEXT": "MDM2"}}, "obj_activity": "activity", "belief": 0.37152225, "evidence": [{"source_api": "reach", "text": "In addition to P5091, a dual inhibitor of USP7 and USP47, compound 1 ( Table 2 ) (IC 50 = 4.2 \u03bcM for USP7 and IC 50 = 4.3 \u03bcM for USP47) [86] accelerated MDM2 degradation in human cancer cell lines and[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]", "annotations": {"found_by": "Positive_activation_syntax_1_verb", "agents": {"raw_text": ["USP47", "MDM2"]}, "prior_uuids": ["a974bfb6-c13d-40ae-a471-142940f5854f"], "content_source": "elsevier"}, "epistemics": {"direct": false, "raw_sections": []}, "text_refs": {"PMID": "33157193", "TRID": 32355039, "PMID_NUM": 33157193, "DOI": "10.1016/J.DRUDIS.2020.10.028", "DOI_NS": 1016, "DOI_ID": "J.DRUDIS.2020.10.028", "PII": "S1359-6446(20)30464-5", "TCID": 88844991, "SOURCE": "elsevier", "RID": 10300088844991, "READER": "REACH"}, "source_hash": -6226856005742733743, "pmid": "33157193"}], "id": "a974bfb6-c13d-40ae-a471-142940f5854f", "matches_hash": "-23606197136376385"}}}